•
Sep 30, 2020
Akero Q3 2020 Earnings Report
Akero Therapeutics reported third quarter financial results for the period ending September 30, 2020.
Key Takeaways
Akero Therapeutics reported strongly positive histological data from their FGF21 analog, efruxifermin (EFX), and raised more than $216 million to enable continued development of EFX.
Reported strongly positive histological data from FGF21 analog, efruxifermin (EFX).
Raised more than $216 million to enable continued development of EFX.
Received feedback from the FDA that enables continuation of EFX development with proposed adaptive Phase 2b/3 clinical trial design.
EFX received PRIME designation from EMA for development as a NASH therapy.
Akero
Akero
Forward Guidance
Akero is focused on advancing the development of Efruxifermin (EFX) for the treatment of NASH.